Decades have passed since the first nanoparticles-base medicine was approved for human
cancer treatment, and the research and development of nanoparticles for drug delivery are …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

DNA materials have emerged as potential nanocarriers for targeted cancer therapy to
precisely deliver cargos with specific purposes. The short half‐life and low bioavailability of …

Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

The cGAS-STING pathway is essential for immune defense against microbial pathogens and
malignant cells; as such, STING is an attractive target for cancer immunotherapy. However …

Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Bioorthogonal chemistry capable of operating in live animals is needed to investigate
biological processes such as cell death and immunity. Recent studies have identified a …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

Modern medicine has been waging a war on cancer for nearly a century with no tangible
end in sight. Cancer treatments have significantly progressed, but the need to increase …